| Document |
Document Title |
|
WO/2017/088829A1 |
Provided is a method for separating human testicular mesenchymal stem cells. The method comprises: digesting a testis sample, separated out by means of biopsy, of an obstructive azoospermia patient with type IV collagenase, and filtering...
|
|
WO/2017/083925A1 |
The present disclosure relates to methods and reagents for treating or preventing metabolic disorders, including, but not limited to, type 2 diabetes, obesity, hyperglycaemia and other conditions associated with an abnormality of glucose...
|
|
WO/2017/084001A1 |
Disclosed is an aquilaria food contributing to the cure of a diabetic nephropathy in a human body, said food comprising plant-derived squalene. By extracting aquilaria by means of carbon dioxide extraction, aquilaria extract is obtained ...
|
|
WO/2017/083794A1 |
Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for ...
|
|
WO/2017/073798A1 |
The present invention addresses the problem of providing nasal drops which can achieve high absorption of oxytocin, which is a peptide hormone, an acid addition salt of oxytocin or a derivative of oxytocin or the acid addition salt throu...
|
|
WO/2017/073764A1 |
The present invention addresses the problem of providing a novel NK3-receptor selective ligand which is expected to have a highly-active/highly-selective and sustained effect in vivo. A compound represented by formula (I) X1-A2-A3-X4-X5-...
|
|
WO/2017/072020A1 |
The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compo...
|
|
WO/2017/072629A1 |
The present invention describes a synergistic composition comprising of NK3 receptor antagonist or a pharmaceutically effective salts thereof and biguanides or a pharmaceutically effective salts thereof for the treatment of PCOS and rela...
|
|
WO/2017/074266A1 |
The invention relates to glyceryl tridecanoate and uses thereof in treating endocrine disorders. More particularly, glyceryl tridecanoate may be used to treat hyper-androgenism, insulin resistance and infertility caused by, for example, ...
|
|
WO/2017/068351A1 |
A solid dosage form for injection and a method of making said dosage form wherein the dosage form has a moisture content of 5% (w/w) or less. The solid dosage form comprises a dried matrix including a first excipient and 0.01 to 50 % (w/...
|
|
WO/2017/070617A1 |
An insulin analogue contains a specific combination of modifications to the A- and B chains: (i) a phenylboronic acid derivative (optionally including a halogen atom substitution) linked by a connecting element either to the alpha-amino ...
|
|
WO/2017/061621A1 |
Provided is a pharmaceutical composition or the like comprising (4-{(3S)-3-[(1R)-1-(naphthalene-1-yl)ethylamino] pyrrolidine-1-yl}phenyl) acetic acid (compound A) or a pharmacologically acceptable salt thereof and excipients.
|
|
WO/2017/060388A1 |
The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject ...
|
|
WO/2017/059726A1 |
Provided in the present invention is a use of a triglyceride compound in the preparation of drugs for treating polycystic ovary syndrome. Also provided in the present invention is a use of a triglyceride compound for preparing a composit...
|
|
WO/2017/057717A1 |
Provided is a heteroaromatic derivative which is represented by general formula (I), has an OX receptor antagonistic activity and is useful as a therapeutic or prophylactic drug for diseases mediated by an OX receptor, or a pharmaceutica...
|
|
WO/2017/057743A1 |
Provided is a transdermally absorbable composition that contains testosterone, and one or more organic solvents selected from the group consisting of propylene glycol, 1,3-butylene glycol, dipropylene glycol and polyethylene glycol, wher...
|
|
WO/2017/050438A1 |
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a pharmaceutically a...
|
|
WO/2017/046124A1 |
A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO:1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism typ...
|
|
WO/2017/047769A1 |
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...
|
|
WO/2017/047777A1 |
Provided is a serotonin deficiency amelioration agent for after stress-load release, that improves serotonin deficiencies after a stress load has been released. The serotonin deficiency amelioration agent for after stress-load release ha...
|
|
WO/2017/043569A1 |
Disclosed are a human serum albumin mutant that links with a bioactive protein and can increase the stability of the protein in the blood, and a protein linked thereto. A human serum albumin mutant including a linked protein that is an a...
|
|
WO/2017/041622A1 |
Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-car
bonyl-2-thioimidazolin-1-yl)-2...
|
|
WO/2017/040363A1 |
A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.
|
|
WO/2017/035619A1 |
The invention relates to a nasal pharmaceutical testosterone formulation and of a series of devices that form a packaging card-shaped pharmaceutical kit for nasal administration of testosterone, the kit being formed by a plurality of the...
|
|
WO/2017/037081A1 |
The present invention relates to new compounds of formula (1) wherein R is -C(=O)CH2OH or -CH(OH)CH2OH; R1, is =O or OH; R2 is H or OH; R3 is H or C1-C4alkyl; R4 is H or C1C4alkyl. These compounds are obtained by a process using at least...
|
|
WO/2017/031918A1 |
The present invention relates to a long-acting dipeptidyl peptidase-IV inhibitor, applications, and a preparation method for an intermediate thereof. Specifically, the present invention relates to a compound represented by general formul...
|
|
WO/2017/029261A1 |
The invention relates to the use of the mineralocorticoid receptor antagonist finerenone combined with an inhibitor of the neutral endopeptidase (NEP), for treating and/or preventing cardiovascular diseases, renal diseases, lung disorder...
|
|
WO/2017/030160A1 |
The present invention identifies and enables the utilization of biofunctional components. The present invention address the problem of providing a novel use for a pork bone extract that includes un- or undercarboxylated osteocalcin (GluO...
|
|
WO/2017/024027A1 |
Liquid polymer pharmaceutical compositions with a biodegradable liquid polyester that has a carboxylic acid end group, a biocompatible solvent, and an active pharmaceutical agent are useful for administration into the body to provide ext...
|
|
WO/2017/021435A1 |
The present invention relates to new compounds useful as antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), and in particular to their use as a non-hormonal male contraceptive. The present invention also relates t...
|
|
WO/2017/022651A1 |
In the present invention, a composition comprising an antibody is adjusted to a state in which an anionic polymer is included at a pH below the antibody pI, and impurities that were insolubilized by the anionic polymer are removed. More ...
|
|
WO/2017/018500A1 |
The present invention addresses the problem of providing a GLP-1 secretagogue, which is an incretin hormone-related drug that is relatively inexpensive and has excellent safety, and which can promote the secretion of GLP-1 without having...
|
|
WO/2017/017301A1 |
The invention relates to novel alpha and eta crystalline forms of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidin
yl)ethyl]-α,α-dimethyl-benzeneacetic acid (bilastine). The invention also relates to methods for the prepara...
|
|
WO/2002/100404A9 |
The present invention is concerned with formulations for use in a method of suppressing hot flushes, especially hot flushes in hypo-estrogenic females and androgen-deprived males. More particularly the invention relates to a pharmaceutic...
|
|
WO/2016/209809A1 |
The present invention relates to, inter alia, a novel crystalline free- plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L- arginine salt of (R)-2-(7...
|
|
WO/2016/202099A1 |
The invention relates to a new pharmaceutical use of terazosin drugs, in particular to the use of the terazosin drugs in terms of anti-aging and body metabolism regulation. The terazosin drugs are compounds of formula I or pharmaceutical...
|
|
WO/2016/204271A1 |
The present invention discloses an immune function development promoter and growth promoter containing CCL25. Taking this immune function development promoter can promote the development of the immune function of a subject. Additionally,...
|
|
WO/2016/200827A1 |
A compound, or a pharmaceutically acceptable salt thereof, having a formula I of: (I) wherein Ar is an arylene or heteroarylene; R1 has a structure of: (II) wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof; X ...
|
|
WO/2016/198663A1 |
New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
|
|
WO/2016/184829A1 |
This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
|
|
WO/2016/187347A1 |
Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.
|
|
WO/2016/178202A1 |
A gelated microparticle suitable for delivery intact to the mammalian lower intestine via an oral route comprises a monodispersed matrix formed of at least partially hydrolysed casein, chitosan, and an active agent, and includes a minor ...
|
|
WO/2016/174551A1 |
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt wherein X, R1-R8, Υ1-Υ5, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders med...
|
|
WO/2016/171165A1 |
A medicine for preventing and/or treating diseases caused by the activation of caspase-1, for example, chronic inflammations or autoinflammatory diseases, said medicine comprising as an active ingredient a compound represented by formula...
|
|
WO/2016/170102A1 |
The present invention relates to the combination of an antiandrogen with a vitamin K antagonist or with a γ-glutamyl carboxylase inhibitor for use in the treatment or prevention of an androgen receptor positive cancer, such as prostate ...
|
|
WO/2016/168222A1 |
The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
|
|
WO/2016/166288A1 |
Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
|
|
WO/2016/168225A1 |
The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
|
|
WO/2016/162495A1 |
The present invention provides a nano particle comprising: a core comprising metal atoms; a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprises: at least one carbohydrate li...
|
|
WO/2016/160881A1 |
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and...
|
